Search research articles
Contact Us
Filters
Showing results (1-10 of 19) with videos related to
Page
of 2
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
July 17, 2015
Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model
Shinji Yamazaki, Theodore R Johnson, Bill J Smith
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
November 7, 2012
Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes
Jialin Mao, Theodore R Johnson, Zhongzhou Shen, et al.
Journal of Drugs in Dermatology : JDD
|
August 13, 2015
Randomized Pilot Clinical Trial of Tofacitinib Solution for Plaque Psoriasis: Challenges of the Intra-Subject Study Design
William C Ports, Steven R Feldman, Pankaj Gupta, et al.
Journal of Clinical Pharmacology
|
May 23, 2020
Metabolism, Excretion, and Pharmacokinetics of Lorlatinib (PF-06463922) and Evaluation of the Impact of Radiolabel Position and Other Factors on Comparability of Data Across 2 ADME Studies
Daria Stypinski, Luke Fostvedt, Justine L Lam, et al.
International Journal of Clinical Pharmacology and Therapeutics
|
April 24, 2014
Integrating disease progression models, non-clinical pharmacokinetic data and treatment response endpoints to optimize intravitreal dosing regimens
Anthony S Basile, Theodore R Johnson, Karen J Klamerus, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
October 19, 2014
Crizotinib reduces the rate of dark adaptation in the rat retina independent of ALK inhibition
Chang-Ning Liu, Nagappan Mathialagan, Patrick Lappin, et al.
Investigative Ophthalmology & Visual Science
|
January 25, 2014
RTP801 gene expression is differentially upregulated in retinopathy and is silenced by PF-04523655, a 19-Mer siRNA directed against RTP801
Kay D Rittenhouse, Theodore R Johnson, Paolo Vicini, et al.
Clinical Drug Investigation
|
December 31, 2016
Effects of Renal Function on Crizotinib Pharmacokinetics: Dose Recommendations for Patients with ALK-Positive Non-Small Cell Lung Cancer
Weiwei Tan, Shinji Yamazaki, Theodore R Johnson, et al.
Investigative Ophthalmology & Visual Science
|
July 28, 2011
Intravitreal concentrations of a near-infrared fluorescence-labeled biotherapeutic determined in situ using confocal scanning laser ophthalmoscopy
Anthony S Basile, Genevieve Glazier, Alice Lee, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
September 16, 2024
Nonclinical Profile of PF-06952229 (MDV6058), a Novel TGFβRI/Activin Like Kinase 5 Inhibitor Supports Clinical Evaluation in Cancer
Mausumee Guha, Stephane Thibault, Son Pham, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 19) with videos related to
Sort By:
Page
of 2
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
July 17, 2015
Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model
Shinji Yamazaki, Theodore R Johnson, Bill J Smith
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
November 7, 2012
Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes
Jialin Mao, Theodore R Johnson, Zhongzhou Shen, et al.
Journal of Drugs in Dermatology : JDD
|
August 13, 2015
Randomized Pilot Clinical Trial of Tofacitinib Solution for Plaque Psoriasis: Challenges of the Intra-Subject Study Design
William C Ports, Steven R Feldman, Pankaj Gupta, et al.
Journal of Clinical Pharmacology
|
May 23, 2020
Metabolism, Excretion, and Pharmacokinetics of Lorlatinib (PF-06463922) and Evaluation of the Impact of Radiolabel Position and Other Factors on Comparability of Data Across 2 ADME Studies
Daria Stypinski, Luke Fostvedt, Justine L Lam, et al.
International Journal of Clinical Pharmacology and Therapeutics
|
April 24, 2014
Integrating disease progression models, non-clinical pharmacokinetic data and treatment response endpoints to optimize intravitreal dosing regimens
Anthony S Basile, Theodore R Johnson, Karen J Klamerus, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
October 19, 2014
Crizotinib reduces the rate of dark adaptation in the rat retina independent of ALK inhibition
Chang-Ning Liu, Nagappan Mathialagan, Patrick Lappin, et al.
Investigative Ophthalmology & Visual Science
|
January 25, 2014
RTP801 gene expression is differentially upregulated in retinopathy and is silenced by PF-04523655, a 19-Mer siRNA directed against RTP801
Kay D Rittenhouse, Theodore R Johnson, Paolo Vicini, et al.
Clinical Drug Investigation
|
December 31, 2016
Effects of Renal Function on Crizotinib Pharmacokinetics: Dose Recommendations for Patients with ALK-Positive Non-Small Cell Lung Cancer
Weiwei Tan, Shinji Yamazaki, Theodore R Johnson, et al.
Investigative Ophthalmology & Visual Science
|
July 28, 2011
Intravitreal concentrations of a near-infrared fluorescence-labeled biotherapeutic determined in situ using confocal scanning laser ophthalmoscopy
Anthony S Basile, Genevieve Glazier, Alice Lee, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
September 16, 2024
Nonclinical Profile of PF-06952229 (MDV6058), a Novel TGFβRI/Activin Like Kinase 5 Inhibitor Supports Clinical Evaluation in Cancer
Mausumee Guha, Stephane Thibault, Son Pham, et al.
Page
of 2